Literature DB >> 29994908

The Effect of Body Mass Index and Weight Change on Late Gastrointestinal Toxicity in Locally Advanced Cervical Cancer Treated With Intensity-modulated Radiotherapy.

Jie Lee, Chih-Long Chang1, Jhen-Bin Lin2, Meng-Hao Wu, Fang-Ju Sun, Chieh-Ju Wu3, Hung-Chi Tai, Shih-Ming Hsu4, Yu-Jen Chen.   

Abstract

OBJECTIVE: To evaluate the effects of body mass index (BMI) and weight change during radiotherapy on the development of toxicity in patients with locally advanced cervical cancer (LACC) treated with intensity-modulated radiotherapy (IMRT).
METHODS: A total of 245 patients were analyzed after undergoing definitive IMRT treatment between 2004 and 2015 for stage IB2 to stage IVA LACC. The patients were divided into 3 groups: underweight (BMI <18.5 kg/m), normal weight (BMI 18.5-24.9 kg/m), and overweight (BMI ≥25.0 kg/m). The relationships between toxicity, clinical factors, and the bowel dose-volume histogram were analyzed. V45 indicated the bowel volume that received a radiation dose of 45 Gy.
RESULTS: The median follow-up period was 63 months. The V45 was similar among the 3 groups. The 5-year rates of grade 3 or higher late gastrointestinal toxicities were 18.6%, 4.0%, and 4.2% for the underweight, normal weight, and overweight groups, respectively (P = 0.002). In the multivariable analysis, underweight (hazard ratio, 13.99; 95% confidence interval, 3.22-60.82; P < 0.001) and weight loss (> -5%) (hazard ratio, 5.91; 95% confidence interval, 1.75-19.98; P = 0.004) were significant predictors of grade 3 or higher-grade late gastrointestinal toxicities.
CONCLUSION: A BMI of less than 18.5 kg/m and weight loss (> -5%) were associated with a higher risk of grade ≥3 or higher late gastrointestinal toxicity in patients with LACC treated with definitive IMRT. Future research on the development of a standardized and structured approach to improve the therapeutic ratio for the supportive care of patients with LACC is needed.

Entities:  

Mesh:

Year:  2018        PMID: 29994908     DOI: 10.1097/IGC.0000000000001312

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.

Authors:  Jie Lee; Jhen-Bin Lin; Meng-Hao Wu; Ya-Ting Jan; Chih-Long Chang; Chueh-Yi Huang; Fang-Ju Sun; Yu-Jen Chen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-05-15       Impact factor: 12.910

2.  Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.

Authors:  Chueh-Yi Huang; Yuh-Cheng Yang; Tze-Chien Chen; Jen-Ruei Chen; Yu-Jen Chen; Meng-Hao Wu; Ya-Ting Jan; Chih-Long Chang; Jie Lee
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-01-30       Impact factor: 12.910

3.  Progressive Skeletal Muscle Loss After Surgery and Adjuvant Radiotherapy Impact Survival Outcomes in Patients With Early Stage Cervical Cancer.

Authors:  Jie Lee; Jhen-Bin Lin; Tze-Chien Chen; Ya-Ting Jan; Fang-Ju Sun; Yu-Jen Chen; Meng-Hao Wu
Journal:  Front Nutr       Date:  2022-01-20

4.  Muscle Loss after Chemoradiotherapy as a Biomarker of Distant Failures in Locally Advanced Cervical Cancer.

Authors:  Jie Lee; Jhen-Bin Lin; Meng-Hao Wu; Chih-Long Chang; Ya-Ting Jan; Yu-Jen Chen
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.